Exelixis (EXEL) Upgraded at BidaskClub

Exelixis (NASDAQ:EXEL) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.

EXEL has been the subject of several other reports. Oppenheimer restated a “hold” rating on shares of Exelixis in a research note on Wednesday, January 17th. Cann restated a “hold” rating on shares of Exelixis in a research note on Monday, October 16th. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price objective for the company in a research note on Tuesday, January 2nd. Needham & Company LLC restated a “buy” rating and set a $30.00 price objective on shares of Exelixis in a research note on Monday, October 2nd. Finally, TheStreet upgraded shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Wednesday, October 18th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Exelixis currently has a consensus rating of “Buy” and a consensus price target of $32.13.

Shares of Exelixis (NASDAQ EXEL) opened at $30.27 on Thursday. Exelixis has a 12 month low of $16.72 and a 12 month high of $32.50. The company has a market cap of $8,900.00, a P/E ratio of 61.78, a price-to-earnings-growth ratio of 0.86 and a beta of 1.88.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.08 by $0.18. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The business had revenue of $152.50 million during the quarter, compared to analysts’ expectations of $104.91 million. During the same period in the previous year, the business posted ($0.04) EPS. The business’s quarterly revenue was up 145.2% compared to the same quarter last year. research analysts forecast that Exelixis will post 0.49 EPS for the current year.

In related news, Director Alan M. Garber sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the transaction, the director now directly owns 64,829 shares in the company, valued at approximately $1,964,318.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 5.10% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Quadrant L P CA lifted its stake in shares of Exelixis by 6,771.4% in the 3rd quarter. First Quadrant L P CA now owns 402,528 shares of the biotechnology company’s stock valued at $9,753,000 after purchasing an additional 396,670 shares during the period. Macquarie Group Ltd. acquired a new position in shares of Exelixis in the 2nd quarter valued at $3,449,000. Stevens Capital Management LP lifted its stake in shares of Exelixis by 55.5% in the 3rd quarter. Stevens Capital Management LP now owns 127,049 shares of the biotechnology company’s stock valued at $3,078,000 after purchasing an additional 45,336 shares during the period. Vident Investment Advisory LLC acquired a new position in shares of Exelixis in the 3rd quarter valued at $783,000. Finally, Schroder Investment Management Group acquired a new position in shares of Exelixis in the 3rd quarter valued at $334,000. Hedge funds and other institutional investors own 80.92% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Exelixis (EXEL) Upgraded at BidaskClub” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/28/exelixis-exel-upgraded-at-bidaskclub.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply